The Goal of The Regenokine® Program is:
- ✓ Reduced Pain
- ✓ Improved flexibility
- ✓ Improved mobility
- ✓ Improved quality of life
Every patient is different and no single treatment, or collection of treatment modalities, will work for all.
The Regenokine® Program pursues a comprehensive approach that is intended to be tailored to the individual needs of each patient. Some modalities may require referral to various external specialists. The Regenokine® Program is a non-surgical treatment approach in the field of orthopedic medicine with the intent to diminish pain, improve function and restore tissue health –collectively resulting in an improvement in quality of life.
An important building block of the Program is an injection therapy with autologous conditioned serum (ACS). The patient’s own blood is processed to obtain a multitude of proteins, growth factors, and cytokines through physiological secretion and separation. These mediators are believed to have anti-inflammatory and other restorative properties that may be beneficial and may lead to diminished pain. Serum and body own proteins are re-injected into painful target areas including joints, spine, tendons, and/or muscles.
This treatment is not appropriate for everyone but doctors applying the Regenokine® Program have found it to be a helpful tool in their fight against pain. Your Regenokine® Program Doctor will determine if you are a potential candidate. Your doctor may also employ drugs and more traditional physical rehabilitation modalities. It is an “all of the above” approach.
Every patient is different and no single treatment, or collection of treatment modalities, will work for all. That is true for the Regenokine® Program, the associated injection therapy, and all other modalities as a potential part of the Program. Your treating physician will evaluate whether you are a candidate for the Regenokine® Program or if other treatment options including surgery may be a more suitable option.
Adverse events reported by patients and/or their doctors after injection therapy with ACS had a combined frequency of <1% of total injections in Europe from 2012 through 2019. The most frequently reported adverse events were painful injection sites, local inflammatory reactions (swelling, heat, pain), and flu‑like symptoms. Injections with ACS have also been studied clinically for safety and effectiveness. Across 5 randomized controlled studies with a total of 750 patients (302 ACS / 448 control) ACS injections had a safety profile comparable to placebo and other therapeutic modalities used in the control groups. One study observed a joint infection after injection with ACS. The most frequently observed adverse events in these studies were joint-related (swelling, pain in the injection site).
An important building block of the Program is an injection therapy with autologous conditioned serum (ACS). The patient’s own blood is processed to obtain a multitude of proteins, growth factors, and cytokines through physiological secretion and separation. These mediators are believed to have anti-inflammatory and other restorative properties that may be beneficial and may lead to diminished pain. Serum and body own proteins are re-injected into painful target areas including joints, spine, tendons, and/or muscles.
This treatment is not appropriate for everyone but doctors applying the Regenokine® Program have found it to be a helpful tool in their fight against pain. Your Regenokine® Program Doctor will determine if you are a potential candidate. Your doctor may also employ drugs and more traditional physical rehabilitation modalities. It is an “all of the above” approach.
Every patient is different and no single treatment, or collection of treatment modalities, will work for all. That is true for the Regenokine® Program, the associated injection therapy, and all other modalities as a potential part of the Program. Your treating physician will evaluate whether you are a candidate for the Regenokine® Program or if other treatment options including surgery may be a more suitable option.
Adverse events reported by patients and/or their doctors after injection therapy with ACS had a combined frequency of <1% of total injections in Europe from 2012 through 2019. The most frequently reported adverse events were painful injection sites, local inflammatory reactions (swelling, heat, pain), and flu‑like symptoms. Injections with ACS have also been studied clinically for safety and effectiveness. Across 5 randomized controlled studies with a total of 750 patients (302 ACS / 448 control) ACS injections had a safety profile comparable to placebo and other therapeutic modalities used in the control groups. One study observed a joint infection after injection with ACS. The most frequently observed adverse events in these studies were joint-related (swelling, pain in the injection site).
